<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01920919</url>
  </required_header>
  <id_info>
    <org_study_id>2013-000242-18</org_study_id>
    <nct_id>NCT01920919</nct_id>
  </id_info>
  <brief_title>Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis</brief_title>
  <acronym>DEXSAR</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Antonius Hospital</source>
  <brief_summary>
    <textblock>
      This trial examines whether low grade suppression of the initial inflammatory process of&#xD;
      sarcoidosis by intervention with low-dose dexamethasone therapy achieves significant&#xD;
      alleviation of (sub-)acute symptoms, improvement in quality of life, increase in work&#xD;
      productivity, and whether this intervention prevents disease progression and reduces total&#xD;
      health-care costs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The orphan disease sarcoidosis causes a major reduction in quality of life and loss of work&#xD;
      productivity, especially in young adults. Most patients are diagnosed between the age of&#xD;
      20-40 years. In sarcoidosis, multiple organs are affected by inflammation; the cause of the&#xD;
      disease is unknown and no curative medication exists. Sarcoidosis invalidates the lives of&#xD;
      most patient for many years.&#xD;
&#xD;
      Although curative (pharmaco) therapy is not on hand, immunosuppressive drugs may control the&#xD;
      symptoms of the disease. These symptoms are caused by the inflammation in multiple organs,&#xD;
      foremost the lungs and the lymphoid system. However, 90% of the sarcoidosis patients receives&#xD;
      no immunosuppressive medication at all during the first months after diagnosis, even though&#xD;
      the immune system is then highly activated and patients suffer from severe complaints like&#xD;
      malaise, fatigue and pain. This wait-and-see policy is common international practice, but&#xD;
      scientific grounds and official guidelines are lacking.&#xD;
&#xD;
      This project examines whether low grade suppression of the initial inflammatory process of&#xD;
      sarcoidosis by intervention with low-dose dexamethasone therapy achieves significant&#xD;
      alleviation of (sub-)acute symptoms, improvement in quality of life, increase in work&#xD;
      productivity, and whether this intervention prevents disease progression and reduces total&#xD;
      health-care costs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in health-related quality of life versus baseline</measure>
    <time_frame>0, 3, 6, 12, 18, 24 months</time_frame>
    <description>The primary outcome measure is the change in health-related quality of life compared with baseline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Dexamethasone 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone 1 mg per day, for 180 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet, for 180 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Dexamethasone 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of sarcoidosis, confirmed by histology or cytology&#xD;
&#xD;
          -  Age 18-60 years&#xD;
&#xD;
          -  No affected organ requiring high dose immunosuppressive therapy&#xD;
&#xD;
          -  Short Form - 36 subscale physical functioning score &lt; 70 points&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to corticosteroids&#xD;
&#xD;
          -  Diagnosis of glaucoma, osteoporosis, history of fractures&#xD;
&#xD;
          -  History of gastric ulcera in the past 12 months&#xD;
&#xD;
          -  Current use of Non Steroidal Anti Inflammatory Drug without co-prescription of Proton&#xD;
             Pump Inhibitor&#xD;
&#xD;
          -  Current use of carbamazepin, fenytoin, rifampicin&#xD;
&#xD;
          -  Obesity (BMI &gt; 30)&#xD;
&#xD;
          -  Pregnancy of lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roeland Vis</last_name>
    <phone>0031 30 609 2612</phone>
    <email>r.vis@antoniusziekenhuis.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roeland Vis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>August 7, 2013</study_first_submitted>
  <study_first_submitted_qc>August 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2013</study_first_posted>
  <last_update_submitted>November 18, 2014</last_update_submitted>
  <last_update_submitted_qc>November 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Antonius Hospital</investigator_affiliation>
    <investigator_full_name>R Vis</investigator_full_name>
    <investigator_title>Hospital Pharmacist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

